Optimisation of region-specific reference gene selection and relative gene expression analysis methods for pre-clinical trials of Huntington's disease
© Benn et al; licensee BioMed Central Ltd. 2008
Received: 10 June 2008
Accepted: 27 October 2008
Published: 27 October 2008
Transcriptional dysregulation is an early, key pathogenic mechanism in Huntington's disease (HD). Therefore, gene expression analyses have biomarker potential for measuring therapeutic efficacy in pre-clinical trials, particularly those aimed at correcting gene expression abnormalities. Housekeeping genes are commonly used as endogenous references in gene expression studies. However, a systematic study comparing the suitability of candidate reference genes for use in HD mouse models has not been performed. To remedy this situation, 12 housekeeping genes were examined to identify suitable reference genes for use in expression assays.
We found that commonly used reference genes are dysregulated at later time points in the R6/2 mouse model of HD. Therefore, in order to reliably measure gene expression changes for use as pre-clinical trial biomarkers, we set out to identify suitable reference genes for use in R6/2 mice. The expression of potential reference genes was examined in striatum, cortex and cerebellum from 15 week old R6/2 and matched wild-type littermates. Expression levels of candidate reference genes varied according to genotype and brain region. GeNorm software was used to identify the three most stably expressed genes for each brain region. Relative quantification methods using the geometric mean of three reference genes for normalisation enables accurate determination of gene expression levels in wild-type and R6/2 mouse brain regions.
Our study has identified a reproducible, reliable method by which we able to accurately determine the relative expression level of target genes in specific brain regions, thus increasing the potential of gene expression analysis as a biomarker in HD pre-clinical trials.
Huntington's disease (HD) is an autosomal dominant, late-onset neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the HD gene which translates into a polyglutamine (polyQ) tract in the huntingtin (Htt) protein . HD thus belongs to a group of neurodegenerative disorders caused by polyQ expansion, which include spinal and bulbar muscular atrophy (SBMA), dentatorubral pallidoluysian atrophy (DRPLA) and the spinocerebellar ataxias (SCA) types 1, 2, 3, 6, 7, and 17 . The polyQ motif occurs in many transcription factors and can function as a transcriptional activation domain. Interestingly, polyQ repeat expansions in TATA binding protein (TBP) and the androgen receptor (AR) cause the disorders SCA17 and SBMA, respectively. Indeed, polyQ repeat containing disease proteins are increasingly implicated as mediators of gene expression, with deranged transcription profiles observed as a result of polyQ repeat expansion [3–10].
Transcriptional dysregulation is a central pathogenic mechanism in HD [11, 12]. Gene expression profiling of in vitro and in vivo models of HD such as the R6/2 mouse model reveals the identities of specifically altered mRNAs that recapitulates those altered in human HD patient brains [13, 14]. Indeed, comparison of gene expression studies shows remarkable concordance between mouse models and human HD brain . Furthermore, expression profiling studies suggest that more accessible tissues such as muscle may be suitable for gene expression analyses , although the use of blood is more controversial [17, 18].
Reverse transcriptase quantitative polymerase chain reaction (qRT-PCR) is a powerful tool to obtain data about gene expression. Normalisation enables one to determine the change in mRNA levels of a gene of interest from multiple samples versus one or more reference gene(s), often a housekeeping gene [19–21]. Reference genes are selected on the basis of constitutive expression across samples to allow the reliable quantification of changes in gene expression . At present, a universally optimal reference gene has not been identified for any organism that can be used across different tissue types or disorders.
Clearly, in a disease such as HD where transcriptional dysregulation is a prominent pathological feature, identification of suitable reference genes throughout the disease time-course is critical. This is amply demonstrated by data showing that beta-actin (Actb), a commonly-used reference, is dysregulated at late time points in R6/2 mouse brain . However, a systematic study comparing the suitability of different candidate reference genes in HD has not been performed. To remedy this situation, 12 housekeeping genes were examined to determine their utility as references in three distinct dissected brain regions from 15 week old R6/2 mice and littermate controls. We found that the expression levels of candidate reference genes varied according to genotype and brain region, highlighting the necessity of identifying suitable references in the tissue or cell line under study. GeNorm software was used to identify the three most stably expressed genes for each brain region, from which the geometric mean was derived as a reliable normalisation value for relative gene expression level analyses. Taken together, we propose that the method outlined in this study can be applied in different tissue samples in order to reliably generate gene expression changes as a biomarker in genetic and pharmacological approaches to modifying HD related phenotypes.
Hemizygous R6/2 transgenic mice were bred and reared in our colony by backcrossing R6/2 males to (CBA × C57Bl/6) F1 females (B6CBAF1/OlaHsd, Harlan Olac, Bicester, UK) . The R6/2 mouse model of HD ubiquitously expresses exon 1 of the human HD gene with over 150 CAG repeats, and develops neuropathology, cognitive and motor symptoms. R6/2 mice were always housed with wild type mice and were subject to a 12-h light: 12-h dark cycle. All animals had unlimited access to water and breeding chow and housing conditions and environmental enrichment were as previously described . R6/2 transgenic mice and wild-type littermate controls were sacrificed by cervical dislocation and brains rapidly removed. Striatum, cortex and cerebellum were dissected and flash-frozen in liquid nitrogen and stored at -80°C until use. The guidelines for animal care and use were in accordance with Home Office regulations.
RNA extraction and reverse transcription
Quantitative RT-PCR (qRT-PCR) represents a powerful tool for detection and quantification of mRNA with high sensitivity, good reproducibility and a wide dynamic range. The principles of qRT-PCR: RNA extraction, reverse transcription (RT), quantitative PCR, fluorescent chemistry and appropriate real-time platforms are all extensively described in the literature [20, 25], and through internet forums http://www.gene-quantification.de/. Each step can directly impact the reliability of the assay and quality assessment is essential to minimise variability (see Additional File 1).
To optimise RNA extraction from dissected brain regions, we use QIAZOL together with RNeasy Mini kits according to the manufacturers protocol (Qiagen), eluting into either 50 μl of RNase-free water for striatal RNA or 100 μl for cerebellar or cortical RNA. We routinely incorporate DNase treatment as part of the RNeasy procedure (Qiagen) to remove any residual DNA, and perform "minus-RT" controls as well as no-template controls in the PCR analyses. In order to improve signal-to-noise ratio, we use dissected brain regions such as striatum, cortex or cerebellum. RNA quality encompasses both purity and integrity, and we use the Agilent Bioanalyser 2100 RNA Nano assay to assess this via the 28S/18S rRNA ratio, and to determine the RNA concentration (see Additional File 1). Valid alternatives include the nanodrop procedure or the use of 3':5' assays .
The RT step is the source of most of the variability and is critically dependent on both enzyme choice and priming method. Target gene-specific primers can be used successfully to eliminate spurious transcripts but then separate RT reactions are needed for each gene of interest, which is inefficient when surveying several genes, and furthermore, different reactions do not have the same cDNA synthesis efficiency. We therefore use MMLV RT-ase (Invitrogen) together with random hexamers to synthesise a cDNA pool which is used for a number of different target-specific qPCR assays (see Additional File 1). In order to minimise variability, we prepare all experimental samples intended for comparison by qRT-PCR in parallel, adding the same amount of RNA template to each RT reaction. Reverse transcription of total RNA (either 5 μg of RNA from cerebellum and cortex or 1 μg of striatal RNA) was performed with MMLV RTase (Invitrogen). The cDNA samples were then cooled to 4°C and diluted 1:10 before storing at -20°C.
Real-time quantitative PCR (qRT-PCR)
QPCR uses fluorescent reporter dyes to combine the amplification and detection steps of the PCR reaction. The qPCR assay relies on measuring the increase in fluorescent signal, which is proportional to the amount of DNA produced during the logarithmic phase of the PCR cycle. Individual reactions are characterised by the PCR cycle at which fluorescence first rises above a defined or threshold background fluorescence, a parameter known as the threshold cycle (Ct). The more target there is in the starting material, the lower the Ct. This correlation between fluorescence and amount of amplified product permits accurate quantification over a wide dynamic range, while retaining the sensitivity and specificity inherent in a conventional PCR. An additional benefit is conferred by reducing variability which can be introduced post-RT-PCR (such as ethidium bromide gel staining and densitometric analysis). We use two methods for the quantitative detection of the amplicon: (a) gene-specific fluorescent Taqman probes, or (b) SYBR green, a non-sequence specific fluorescent intercalating double-stranded DNA binding dye. Both types of reaction can work extremely well, with comparable dynamic range and sensitivity. An additional advantage conferred by the Taqman system is the use of probes labelled with different reporter dyes, allowing the detection and quantification of multiple target genes in a single (multiplex) reaction.
Primer and probe lists.
PROBE (5' FAM, 3' TAMRA)
Finally, the quantification strategy must be considered. Absolute quantification correlates the PCR signal to input copy number using a calibration curve, and is dependent on equivalent amplification efficiencies for both the native target and the calibration curve. Absolute quantification should be performed in situations where it is necessary to determine the transcript copy number, such as determining the titre of virus particles in blood. In contrast, relative quantification measures the relative change in mRNA expression levels and is easier to perform than absolute quantification because a calibration curve is not necessary. Relative quantification is based on the expression levels of target gene(s) versus reference gene(s) and the relative quantities can be compared across multiple experiments. We use relative quantification when considering genetic and/or pharmacological modulation of HD related phenotypes. With respect to understanding the effect of a manipulation in a pathogenic pathway, it is more informative to state that a given treatment increases the expression of gene A by 5 fold, than if we state that the treatment increases the expression of gene A from 1000 copies to 5000 copies per cell . Various mathematical models have been established to calculate the expression of a target gene in relation to an adequate reference, based on the comparison of the distinct cycle threshold values (Ct) at a constant level of fluorescent with, or without PCR efficiency correction. We use a well-characterised 2-ΔΔCt equation, as our target and reference PCR amplicons are generated with equivalent efficiencies .
Data analysis using the 2-ΔΔCtmethod
The Ct values provided from real-time PCR instrumentation are easily imported into a spreadsheet programme such as Microsoft Excel. When designing the experiment, we aim for an n ≥ 6 per group and whenever possible, reactions are performed in triplicate for both samples and controls. During 2-ΔΔCt analysis, each sample is treated separately (see Additional File 2). We first ensure that the data from each triplicate fall within 1 Ct and remove clear outliers (> 2 standard deviations) from the analysis. We determine the mean Ct and standard deviation (SD) from the triplicates and use the means of each sample for analysis. The first step of analysis (ΔCt) is to normalise all the samples with respect to the least expressed sample, thus subtracting the highest Ct value from the Ct value of each sample. In this step, the least expressed sample will have a ΔCt value of 0 and all the other samples will have negative values (see Additional File 2). The second step is to perform the function (ΔCt sample - ΔCt reference), which gives a ΔΔCt value. The third step is to calculate 2-ΔΔCt, which yields the expression ratio (as a positive integer) for each individual sample. After performing the 2-ΔΔCt calculation for each sample, we calculate the means for each group in addition to determining the standard deviation and standard error of the mean (SEM) thus providing a relative expression ratio (in arbitrary units) and variation between ratios (see Additional File 2). The expression ratio data are amenable to statistical tests.
Dysregulation of commonly-used normalisation genes in aged R6/2 mice
Identification of suitable reference genes in dissected brain regions
Given the progressive nature of the transcriptional dysregulation phenotype in the R6/2 mice, with down-regulation of commonly used reference genes such as Actb, it was critical to determine which genes were most suitable for normalisation at later time points. However, to validate the stable expression of a given control gene, prior knowledge of a reliable measure to normalise this gene is required. In order to circumvent this circular problem, we took advantage of the principle that the expression ratio of two ideal internal control genes will be near-identical in all samples tested, regardless of the experimental condition . We therefore utilized the geNorm Housekeeping Gene Selection Kit (PrimerDesign) to evaluate 12 commonly used housekeeping genes  in 3 different dissected brain regions from 15 week old wild-type and R6/2 mice. Reference genes tested were 18S (18S ribosomal RNA subunit), Actb (beta-actin), Atp5b (ATP synthase subunit 5b), B2m (beta-2 microglobulin), Canx (calnexin), Cyc1 (cyclin D1), Eif4a2 (eukaryotic initiation factor 4a2), Gapdh (glyceraldehyde-3-phosphate dehydrogenase), Rpl13a (ribosomal protein L13a), Sdha (succinate dehydrogenase complex, subunit A), Ubc (ubiquitin C) and Yhwaz (phospholipase A2).
Control genes ranked in order of their expression stability.
Brain tissue is not homogenous and is composed of widely differing cell types. Consistent with this, microarray analysis of distinct brain regions and cell types shows highly specific transcriptional profiles [27–31]. We therefore set out to determine whether the optimal reference genes identified for use in striatum were also suitable for use as references in two other brain regions, the cerebellum and the cerebral cortex. GeNorm analysis was performed using RNA prepared from dissected cerebellum (see Additional File 3) and cortex (see Additional File 4) in precisely the same manner as for the striatum. We found that the tissue source determined the choice of genes for normalisation, with Canx (calnexin), Atp5b and Eif4a2 identified for normalisation in the cerebellum; and Atp5b, Rpl13a (ribosomal protein L13a) and Canx being suitable choices for the cortex. The cortex showed more expression stability variation than either the striatum or cerebellum, which may reflect a greater heterogeneity in cell types and function.
Validation of reference genes identified through geNorm analyses
The geNorm analyses identified the most stably expressed tissue-specific reference genes from our initial panel of twelve candidates. We concluded that in order to measure expression levels of our genes of interest accurately by relative quantification, normalization by multiple housekeeping genes would be more robust. We therefore chose to use the geometric mean of at least the best three reference genes identified for each tissue in our analyses as it indicates the central tendency, or typical value of a set of numbers . Furthermore, the geometric mean is more appropriate than the arithmetic mean as we would expect that changes in the gene expression would occur in a relative fashion and hence we can control better for possible outlying values and abundance differences between the different genes. In order to establish relative expression analyses for dysregulated genes in the striatum of R6/2 mice, we first confirmed that the dynamic Ct range of the reference genes was equivalent to the majority of our genes of interest and that the amplification efficiencies of the reference genes and genes of interest were equivalent.
BDNF expression analyses
Recent advances in gene quantification strategies enable the rapid and precise quantification of RNA transcripts. Normalisation is required to remove sampling differences (such as RNA quantity and quality) in order to identify real gene-specific variation. Accurate normalisation of gene expression levels is therefore a prerequisite, especially when studying the biological significance of subtle gene expression differences. The majority of laboratories use a single control gene for normalisation purposes in RT-PCR (both "classical" and real-time RT-PCR), with Actb, Gapdh and ribosomal RNA being used in over 90% of cases . However, housekeeping gene expression can vary considerably, with obvious impact on meaningful data interpretation. For example, it has been reported that B2m (beta-2-microglobulin, a commonly used reference gene) is variably expressed in neuroblastoma cells, depending on the differentiation state of the tumour cells , warranting the validation of a reference gene in each experimental system. Additionally, a study showed that a set of genes, including Actb varied in expression by 7 to 23-fold across a panel of 60 cell lines [43, 44]. In this regard, identifying suitable control genes for normalisation is even more important when working with complex tissues such as brain regions, or with tissues of different histological origins. Consistent with previously published data , we found that a commonly used reference gene, Actb is specifically dysregulated at later time-points in R6/2 mouse brain regions. Therefore, the use of Actb as an appropriate single control normalisation factor is inappropriate, particularly at later time points. This is troubling, as Actb appears to be one of the most commonly used normalisation genes in expression analyses in HD.
Clearly, in a disease such as HD, where transcriptional dysregulation is a central pathogenic mechanism , it is critical to identify suitable reference genes throughout the disease time-course. However to date, there has been no systematic study comparing the suitability of different candidate reference genes in HD. We therefore chose to survey a panel of 12 housekeeping genes in an unbiased fashion. We found that the expression levels of candidate reference genes varied according to genotype and brain region, highlighting the necessity of identifying suitable references in the tissue under study. Specifically, the three most stable genes for each brain region tested as identified by geNorm analysis (striatum, cerebellum and cortex) are distinct, with only one gene being common to all three (Atp5b). This is consistent with the notion that there are highly specific transcriptional profiles in distinct brain regions and cell types.
It has been shown that a conventional normalisation strategy based on a single reference gene can lead to erroneous normalisation up to 6-fold . We therefore propose that a more stringent normalisation strategy should be incorporated, particularly when studying potentially subtle effects upon gene expression levels of a pharmaceutical agent or a genetic modulation strategy. It has been demonstrated that calculating the geometric mean of three reference genes yields a reliable normalisation value, which can then be used to determine relative expression ratios for genes of interest . We therefore surveyed the effect of three different normalisation strategies. We found a stable reference gene to use as a single normaliser is superior to a gene whose expression is unstable between the experimental conditions. However, calculating the geometric mean of three stably expressed reference genes and subsequently using this normalisation factor in subsequent analyses is preferable. Thus, it is critical not only to identify the most suitable reference genes for expression analyses by an unbiased method in the tissue/cell line of interest, but also to utilise a precise normalising strategy in order to derive meaningful results. This is particularly applicable to studies interrogating the molecular mechanism underlying HD pathogenesis and mechanisms by which a particular intervention may exert a beneficial effect.
Bdnf gene transcription is induced by wild-type, but not mutant Htt through interactions with NRSF . In addition, Bdnf mRNA and protein levels are severely decreased in the cortices of numerous HD murine models as well as in post-mortem human HD cortex . Interestingly, gene expression profiling of multiple HD mouse models and comparison to human HD brain suggests that Bdnf depletion plays a major role in striatal degeneration . Remarkably, of all HD mouse models, transcriptional profiles of Bdnf knock-out mice are the most similar to gene expression changes identified in HD human brain, suggesting that decreased Bdnf expression is a key pathogenic feature in HD, possibly through reduced corticostriatal BDNF transport [33, 38]. Furthermore, BDNF levels influence HD onset and progression and up-regulating Bdnf expression in HD mouse models through exercise, environmental enrichment, treatment with compounds or by adenoviral injection have all shown promise in ameliorating HD-related symptoms [33, 34, 36, 45, 46]. Therefore, there is precedence for Bdnf modulation as a therapeutic approach in HD. Taken together, it is critical that we can reliably measure Bdnf levels, either when directly attempting to modulate Bdnf expression; or for use as a biomarker in the context of other disease-modifying therapies, particularly those aimed at correcting gene expression deficits, such as histone deacetylase inhibitors [22, 47–51]. We have therefore developed and validated Taqman-based real-time assays for promoter-specific Bdnf gene expression in the cortex of R6/2 mice. Indeed, in this context, we have expanded the scope of interrogating Bdnf expression with respect to HD. Bdnf gene structure and regulation is complex, with upstream transcription start sites spliced to a coding exon, yielding distinct pro-Bdnf molecules which are cleaved to yield a mature BDNF protein. The complexity of the Bdnf gene facilitates precise regulation of BDNF with respect to the diversity of its functions. Previously reported investigations into Bdnf gene expression dysregulation were based on the four originally described distinctive promoters in the Bdnf gene [32–38]. However, the previous work on Bdnf's gene structure was incomplete, and it has recently been extended with the identification of six upstream transcription start sites spliced (either bipartite or tripartite) to a major coding exon  (see Additional File 5). We have capitalised on the more detailed knowledge of Bdnf gene structure by designing promoter-specific Taqman assays. We have therefore not only confirmed previously published promoter-specific dysregulation in the R6/2 mouse model of HD, but expanded this knowledge. Of particular interest, we have designed specific assays from each of the variants arising from alternative splicing events through the intra-exonic splice sites in promoter II, which has previously been shown to be down-regulated in the R6/2 striatum. Specifically, we have shown that while all three splice variants from Bdnf promoter II are dysregulated, Bdnf transcript IIa is progressively dysregulated to a further extent and is more statistically significant. Furthermore, power calculations suggest that we can effectively use Bdnf expression analyses as an output measure in a pre-clinical trial. Finally, recently published data has suggested that Bdnf expression dysregulation occurs in a cell-autonomous property in HD . Consistent with this, it appears that gene expression dysregulation may be an intrinsic function of mutant Htt protein, although the precise molecular mechanism remains to be determined [53, 54].
Transcriptional dysregulation is a central pathogenic molecular mechanism in HD, with robust, reproducible and early changes in the expression of specific mRNA moieties. Therefore, analysis of gene expression could be valuable as a biomarker to monitor disease progression and the efficacy of therapeutic agents in clinical trials. However, commonly used reference genes and current methods in the HD field are unsuitable for gene expression analysis. We suggest an improvement on previous methods by demonstrating the identification of suitable and reliable reference genes for dissected brain regions of R6/2 mice, which can be applied to other brain regions, tissues or cell lines. In addition, we illustrate a more robust method for analysis, namely using the geometric mean of three reference genes for relative quantification analyses. These improvements are not novel in that they have been previously described and extensively used in other disease fields. However, they are not routinely used within the HD field. We therefore propose that the methods outlined in this study can be applied in different tissues (including biopsies) and cell lines in order to reliably and accurately determine the relative expression level of target genes in these brain regions, thus increasing the potential of gene expression analysis as a biomarker in HD.
Detailed methods and statistical analyses are available as a supplementary section (see Additional File 6).
List of Abbreviations Used
brain derived neurotrophic factor
polymerase chain reaction
quantitative real-time PCR
Funding was provided by the Wellcome Trust (66270) and the CHDI Foundation. The authors would like to thank Ben Woodman for management of the mouse colony, Jude Nixon for help with statistical analysis, Dr Rachel Butler, Dr Kirupa Sathasivam and Dr Ghazaleh Sadri-Vakili for critical reading of the manuscript and helpful discussions.
- Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell. 1993, 72: 971-983. 10.1016/0092-8674(93)90585-E.View ArticleGoogle Scholar
- Bates GP, Harper PS, Jones AL: Huntington's Disease. Edited by: Bates GP, Harper PS, Jones AL. 2002, Oxford: Oxford University Press, 3Google Scholar
- Luthi-Carter R, Strand AD, Hanson SA, et al: Polyglutamine and transcription: gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects. Hum Mol Genet. 2002, 11: 1927-1937. 10.1093/hmg/11.17.1927.View ArticlePubMedGoogle Scholar
- McMahon SJ, Pray-Grant MG, Schieltz D, Yates JR, Grant PA: Polyglutamine-expanded spinocerebellar ataxia-7 protein disrupts normal SAGA and SLIK histone acetyltransferase activity. Proc Natl Acad Sci USA. 2005, 102: 8478-8482. 10.1073/pnas.0503493102.PubMed CentralView ArticlePubMedGoogle Scholar
- Wang L, Rajan H, Pitman JL, McKeown M, Tsai CC: Histone deacetylase-associating Atrophin proteins are nuclear receptor corepressors. Genes Dev. 2006, 20: 525-530. 10.1101/gad.1393506.PubMed CentralView ArticlePubMedGoogle Scholar
- Evert BO, Araujo J, Vieira-Saecker AM, et al: Ataxin-3 represses transcription via chromatin binding, interaction with histone deacetylase 3, and histone deacetylation. J Neurosci. 2006, 26: 11474-11486. 10.1523/JNEUROSCI.2053-06.2006.View ArticlePubMedGoogle Scholar
- Helmlinger D, Hardy S, Abou-Sleymane G, et al: Glutamine-expanded ataxin-7 alters TFTC/STAGA recruitment and chromatin structure leading to photoreceptor dysfunction. PLoS Biol. 2006, 4: e67-10.1371/journal.pbio.0040067.PubMed CentralView ArticlePubMedGoogle Scholar
- Helmlinger D, Hardy S, Eberlin A, Devys D, Tora L: Both normal and polyglutamine-expanded ataxin-7 are components of TFTC-type GCN5 histone acetyltransferase-containing complexes. Biochem Soc Symp. 2006, 155-163.Google Scholar
- Goold R, Hubank M, Hunt A, et al: Down-regulation of the dopamine receptor D2 in mice lacking ataxin 1. Hum Mol Genet. 2007, 16: 2122-2134. 10.1093/hmg/ddm162.View ArticlePubMedGoogle Scholar
- Haecker A, Qi D, Lilja T, et al: Drosophila brakeless interacts with atrophin and is required for tailless-mediated transcriptional repression in early embryos. PLoS Biol. 2007, 5: e145-10.1371/journal.pbio.0050145.PubMed CentralView ArticlePubMedGoogle Scholar
- Luthi-Carter R, Cha JH: Mechanisms of transcriptional dysregulation in Huntington's disease. Clin Neurosci. Res. 2003, 3: 165-177. 10.1016/S1566-2772(03)00059-8.View ArticleGoogle Scholar
- Cha JH: Transcriptional signatures in Huntington's disease. Prog Neurobiol. 2007, 83: 228-248. 10.1016/j.pneurobio.2007.03.004.PubMed CentralView ArticlePubMedGoogle Scholar
- Luthi-Carter R, Strand A, Peters NL, et al: Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet. 2000, 9: 1259-1271. 10.1093/hmg/9.9.1259.View ArticlePubMedGoogle Scholar
- Hodges A, Strand AD, Aragaki AK, et al: Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet. 2006, 15: 965-977. 10.1093/hmg/ddl013.View ArticlePubMedGoogle Scholar
- Kuhn A, Goldstein DR, Hodges A, et al: Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet. 2007, 16: 1845-1861. 10.1093/hmg/ddm133.View ArticlePubMedGoogle Scholar
- Strand AD, Aragaki AK, Shaw D, et al: Gene expression in Huntington's disease skeletal muscle: a potential biomarker. Hum Mol Genet. 2005, 14: 1863-1876. 10.1093/hmg/ddi192.View ArticlePubMedGoogle Scholar
- Borovecki F, Lovrecic L, Zhou J, et al: Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc Natl Acad Sci USA. 2005, 102: 11023-11028. 10.1073/pnas.0504921102.PubMed CentralView ArticlePubMedGoogle Scholar
- Runne H, Kuhn A, Wild EJ, et al: Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci USA. 2007, 104: 14424-14429. 10.1073/pnas.0703652104.PubMed CentralView ArticlePubMedGoogle Scholar
- Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001, 25: 402-408. 10.1006/meth.2001.1262.View ArticlePubMedGoogle Scholar
- Pfaffl MW: Quantification strategies in real-time PCR. A-Z of quantitative PCR. Edited by: Bustin SA. 2001, La Jolla: International University LineGoogle Scholar
- Vandesompele J, De Preter K, Pattyn F, et al: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 2002, 3: RESEARCH0034-10.1186/gb-2002-3-7-research0034.PubMed CentralView ArticlePubMedGoogle Scholar
- Sadri-Vakili G, Bouzou B, Benn CL, et al: Histones associated with downregulated genes are hypo-acetylated in Huntington's disease models. Hum Mol Genet. 2007, 16: 1293-1306. 10.1093/hmg/ddm078.View ArticlePubMedGoogle Scholar
- Mangiarini L, Sathasivam K, Seller M, et al: Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell. 1996, 87: 493-506. 10.1016/S0092-8674(00)81369-0.View ArticlePubMedGoogle Scholar
- Woodman B, Butler R, Landles C, et al: The Hdh(Q150/Q150) knock-in mouse model of HD and the R6/2 exon 1 model develop comparable and widespread molecular phenotypes. Brain Res Bull. 2007, 72: 83-97. 10.1016/j.brainresbull.2006.11.004.View ArticlePubMedGoogle Scholar
- Nolan T, Hands RE, Bustin SA: Quantification of mRNA using real-time RT-PCR. Nat Protoc. 2006, 1: 1559-1582. 10.1038/nprot.2006.236.View ArticlePubMedGoogle Scholar
- Weiss A, Klein C, Woodman B, et al: Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington's disease. J Neurochem. 2008, 104: 846-858.PubMedGoogle Scholar
- Nadler JJ, Zou F, Huang H, et al: Large-scale gene expression differences across brain regions and inbred strains correlate with a behavioral phenotype. Genetics. 2006, 174: 1229-1236. 10.1534/genetics.106.061481.PubMed CentralView ArticlePubMedGoogle Scholar
- Schulz DJ, Goaillard JM, Marder EE: Quantitative expression profiling of identified neurons reveals cell-specific constraints on highly variable levels of gene expression. Proc Natl Acad Sci USA. 2007, 104: 13187-13191. 10.1073/pnas.0705827104.PubMed CentralView ArticlePubMedGoogle Scholar
- Stansberg C, Vik-Mo AO, Holdhus R, et al: Gene expression profiles in rat brain disclose CNS signature genes and regional patterns of functional specialisation. BMC Genomics. 2007, 8: 94-10.1186/1471-2164-8-94.PubMed CentralView ArticlePubMedGoogle Scholar
- Strand AD, Aragaki AK, Baquet ZC, et al: Conservation of regional gene expression in mouse and human brain. PLoS Genet. 2007, 3: e59-10.1371/journal.pgen.0030059.PubMed CentralView ArticlePubMedGoogle Scholar
- Cahoy JD, Emery B, Kaushal A, et al: A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J Neurosci. 2008, 28: 264-278. 10.1523/JNEUROSCI.4178-07.2008.View ArticlePubMedGoogle Scholar
- Zuccato C, Ciammola A, Rigamonti D, et al: Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science. 2001, 293: 493-498. 10.1126/science.1059581.View ArticlePubMedGoogle Scholar
- Canals JM, Pineda JR, Torres-Peraza JF, et al: Brain-derived neurotrophic factor regulates the onset and severity of motor dysfunction associated with enkephalinergic neuronal degeneration in Huntington's disease. J Neurosci. 2004, 24: 7727-7739. 10.1523/JNEUROSCI.1197-04.2004.View ArticlePubMedGoogle Scholar
- Zuccato C, Liber D, Ramos C, et al: Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol Res. 2005, 52: 133-139. 10.1016/j.phrs.2005.01.001.View ArticlePubMedGoogle Scholar
- Zuccato C, Marullo M, Conforti P, Macdonald ME, Tartari M, Cattaneo E: Systematic Assessment of BDNF and Its Receptor Levels in Human Cortices Affected by Huntington's Disease. Brain Pathol. 2008, 18: 225-238. 10.1111/j.1750-3639.2007.00111.x.View ArticlePubMedGoogle Scholar
- Gharami K, Xie Y, An JJ, Tonegawa S, Xu B: Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J Neurochem. 2008, 105: 369-379. 10.1111/j.1471-4159.2007.05137.x.PubMed CentralView ArticlePubMedGoogle Scholar
- Zuccato C, Cattaneo E: Role of brain-derived neurotrophic factor in Huntington's disease. Prog Neurobiol. 2007, 81: 294-330. 10.1016/j.pneurobio.2007.01.003.View ArticlePubMedGoogle Scholar
- Strand AD, Baquet ZC, Aragaki AK, et al: Expression profiling of Huntington's disease models suggests that brain-derived neurotrophic factor depletion plays a major role in striatal degeneration. J Neurosci. 2007, 27: 11758-11768. 10.1523/JNEUROSCI.2461-07.2007.View ArticlePubMedGoogle Scholar
- Liu QR, Lu L, Zhu XG, Gong JP, Shaham Y, Uhl GR: Rodent BDNF genes, novel promoters, novel splice variants, and regulation by cocaine. Brain Res. 2006, 1067: 1-12. 10.1016/j.brainres.2005.10.004.View ArticlePubMedGoogle Scholar
- Hockly E, Woodman B, Mahal A, Lewis CM, Bates GP: Standardization and statistical approaches to therapeutic trials in the R6/2 mouse. Brain Res Bull. 2003, 61 (5): 469-479. 10.1016/S0361-9230(03)00185-0.View ArticlePubMedGoogle Scholar
- Suzuki T, Higgins PJ, Crawford DR: Control selection for RNA quantitation. Biotechniques. 2000, 29: 332-337.PubMedGoogle Scholar
- Cooper MJ, Hutchins GM, Mennie RJ, Israel MA: Beta 2-microglobulin expression in human embryonal neuroblastoma reflects its developmental regulation. Cancer Res. 1990, 50: 3694-3700.PubMedGoogle Scholar
- Ross DT, Scherf U, Eisen MB, et al: Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet. 2000, 24: 227-235. 10.1038/73432.View ArticlePubMedGoogle Scholar
- Warrington JA, Nair A, Mahadevappa M, Tsyganskaya M: Comparison of human adult and fetal expression and identification of 535 housekeeping/maintenance genes. Physiol Genomics. 2000, 2: 143-147.PubMedGoogle Scholar
- Bemelmans AP, Horellou P, Pradier L, Brunet I, Colin P, Mallet J: Brain-derived neurotrophic factor-mediated protection of striatal neurons in an excitotoxic rat model of Huntington's disease, as demonstrated by adenoviral gene transfer. Hum Gene Ther. 1999, 10: 2987-2997. 10.1089/10430349950016393.View ArticlePubMedGoogle Scholar
- Spires TL, Grote HE, Varshney NK, et al: Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci. 2004, 24: 2270-2276. 10.1523/JNEUROSCI.1658-03.2004.View ArticlePubMedGoogle Scholar
- Steffan JS, Bodai L, Pallos J, et al: Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature. 2001, 413: 739-743. 10.1038/35099568.View ArticlePubMedGoogle Scholar
- Hockly E, Richon VM, Woodman B, et al: Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA. 2003, 100: 2041-2046. 10.1073/pnas.0437870100.PubMed CentralView ArticlePubMedGoogle Scholar
- Gardian G, Browne SE, Choi DK, et al: Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem. 2005, 280: 556-563.View ArticlePubMedGoogle Scholar
- Butler R, Bates GP: Histone deacetylase inhibitors as therapeutics for polyglutamine disorders. Nat Rev Neurosci. 2006, 7: 784-796. 10.1038/nrn1989.View ArticlePubMedGoogle Scholar
- Sadri-Vakili G, Cha JH: Histone deacetylase inhibitors: a novel therapeutic approach to Huntington's disease (complex mechanism of neuronal death). Curr Alzheimer Res. 2006, 3: 403-408. 10.2174/156720506778249407.View ArticlePubMedGoogle Scholar
- Brown TB, Bogush AI, Ehrlich ME: Neocortical expression of mutant huntingtin is not required for alterations in striatal gene expression or motor dysfunction in a transgenic mouse. Hum Mol Gen. 2008, Jul 16.,
- Runne H, Régulier E, Kuhn A, et al: Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci. 2008, 28 (39): 9723-9731. 10.1523/JNEUROSCI.3044-08.2008.View ArticlePubMedGoogle Scholar
- Benn CL, Sun T, Sadri-Vakili G, et al: Huntingtin modulates transcription, occupies gene promoters in vivo and binds directly to DNA in a polyglutamine-dependent manner. J Neurosci. 2008, 28 (42): 10720-10733. 10.1523/JNEUROSCI.2126-08.2008.PubMed CentralView ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.